A Phase 4 interventional study of Evolocumab or Alirocumab in Lipid Lowering, Vascular Inflammation, sponsored by Rigshospitalet, Denmark. Withdrawn at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-14.
Sponsored by Rigshospitalet, Denmark · Phase 4, Interventional, and Other
This study aim to detect change in vascular inflammation following intense lipid lowering therapy
3,439 studies on the registry are indexed under Inflammation; 629 are open to participants now.
Browse Inflammation studies →Rigshospitalet, Denmark is the lead sponsor of 1,017 studies on the registry; 183 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Evolocumab or Alirocumab
All patients are treated with PCSK-9 inhibitors (Evolocumab or Alirocumab) to lower cholesterol
Change in vascular inflammation
Change in standard uptake value (SUV) of flourdeoxyglucose (FDG) before and after initiation of lipid lowering therapy
Time frame: 12 weeks
This study is withdrawn, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rigshospitalet, Denmark